Replies to post #21700 on Biotech Values

[Praveen]

Vertex. Nope not even close. The one see close to it is SCH503034.

In two studies presented at AASLD 2005, 61 genotype-1 patients in a 14-day course of treatment (5
treatment arms including 1 placebo arm), showed an HCV RNA reduction with the maximum HCV reduction of
more than 2 logs in the group receiving 400 mg of SCH503034. SCH503034 was safe and well-tolerated with no
serious adverse events. In another study, SCH503034 in combination with Peg-Intron resulted in a decrease of more
than 2 logs overall with 4 out of 10 subjects in the 400 mg arm achieving undetectable HCV RNA. Phase II studies
with the combination of SCH503034 are underway.

Also Novartis has NMC 283. Can't remember it's values right at the moment.

Dr.Praveen
PS:Bought it at 10 and sold at 27$ due to valuation concern:-(

Hi Randy, I have a pdf on Hep c rx if you are interested.